← All trials
NCT05240898
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 16, 2021
- Primary completion
- Dec 19, 2023
- Completion date
- Oct 15, 2024
- First posted
- Feb 15, 2022
- Last posted
- Apr 6, 2022
- Enrollment
- 140
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- KSQ Therapeutics, Inc.Lead sponsor
- KSQ Therapeutics, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.